Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;103:23-32.
doi: 10.1016/j.jsat.2019.05.007. Epub 2019 May 7.

Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans

Affiliations
Free PMC article

Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans

Kevin L Kraemer et al. J Subst Abuse Treat. 2019 Aug.
Free PMC article

Abstract

Background: Substance use disorders (SUDs) are common in healthcare settings and contribute to poor outcomes, particularly in patients living with HIV. We assessed initiation, engagement, and retention in SUD treatment and pharmacotherapy following an index SUD episode in a national sample of HIV-infected and uninfected patients receiving care in the Department of Veterans Affairs (VA) healthcare system.

Methods: We used electronic national VA data (years 2000-2015) from 52,995 HIV-infected and 111,229 age-, race-, gender-, and region-matched uninfected patients. We defined index SUD episodes as outpatient visits or inpatient/residential admissions with associated primary or secondary ICD-9 codes for substance use in patients without SUD-related services or pharmacotherapy in the preceding 5 months.

Results: Overall, 57,428 (35%) patients had at least 1 index SUD episode. HIV-infected patients were more likely than uninfected controls to have at least one index SUD episode (35.7% vs. 34.6%; p < .001). Rates of initiation, engagement, and retention in SUD treatment after the index SUD episode were <17% for both groups. In adjusted models, HIV-infected patients were more likely than uninfected patients to be retained in SUD treatment at 6 months (Odds Ratio 1.10; 95% Confidence Interval 1.04-1.16). SUD pharmacotherapy initiation and engagement was uncommon in both HIV-infected and uninfected patients.

Conclusions: In this national VA sample, initiation of SUD treatment and pharmacotherapy were uncommon for both HIV-infected and uninfected patients. Interventions to improve initiation, engagement, and retention in the full range of services, including SUD pharmacotherapy, are warranted for all patients with SUD in the VA.

Keywords: HIV; Opioid treatment; Pharmacotherapy; Substance use disorder treatment; Substance use disorders.

Conflict of interest statement

Conflict of Interest: No conflict declared.

Figures

Fig. 1.
Fig. 1.
Trends over time in opioid agonist therapy following a new clinical episode for opioid use disorder, by HIV infection status. a. Trends in methadone initiation *Test for trend is statistically significant for uninfected (P=.002), but not for HIV-infected b. Trends in burprenorphine initiation *Test for trend is statistically significant for both HIV-infected and uninfected (both P<.001)
Fig. 2.
Fig. 2.
Trends over time in alcohol pharmacotherapy agonist therapy following a new clinical episode for alcohol use disorder, by HIV infection status. a. Trends in acamprosate use *Test for trend is statistically significant for both HIV-infected (P<.001) and uninfected (P<.01) b. Trends in oral naltrexone use *Test for trend is statistically significant for both HIV-infected and uninfected (P<.001 for both)

Similar articles

Cited by 12 articles

Publication types